I operate at the intersection of AI, human genetics, and commercial strategy. At Genomics, I help pharmaceutical and biotech organizations bring large-scale human genetics into earlier, more confident R&D decision-making—through a combination of advanced analytics, AI-enabled tooling, and strategic consulting support.

My work centers on partnering with senior R&D, statistical genetics, and strategy leaders to operationalize genetics across the pipeline: accelerating target discovery, strengthening validation, improving translational confidence, and identifying patient populations more likely to respond to therapy.

Over the past 20 years, I’ve:

•	Built, led, and mentored high-performing sales teams in AI and SaaS.
•	Managed global accounts and developed go-to-market strategies that drive adoption.
•	Closed multi-million-dollar enterprise engagements and partnerships across R&D industries 
•	Negotiated strategic agreements that expand revenue and accelerate growth.

I’m also the author of Mastering AI Sales: Essential Knowledge for B2B Professionals, a practical playbook that equips founders, consultants, and sales leaders with frameworks to win complex AI sales.
👆 Now available – click the link in my profile header to get your copy.

Specialties

•	AI-Enabled Human Genetics / Genomics Commercial Strategy
•	Building & Scaling Sales Teams
•	Enterprise AI Sales & Stakeholder Management
•	Go-to-Market Strategy (Consulting + Product Hybrid Models)
•	Strategic Partnerships & Revenue Expansion
•	Cross-Functional Leadership & Commercial Alignment

Let’s connect if you’re scaling AI solutions, leading enterprise transformations, or looking to accelerate sales impact in complex markets.

David Walker

Early JPM takeaways…

• Causal genetics is firmly front and center, increasingly used to de-risk target identification and validate programs earlier in development.
• Patient stratification is no longer optional. Leaders are entering the clinic with greater emphasis on clear responder hypotheses and stronger supporting evidence.
• AI is maturing quickly. Fewer proof-of-concept discussions, more concrete examples of measurable impact across R&D.
• Funding sentiment appears cautiously improved, particularly for companies with differentiated science and disciplined, evidence-led strategies.

The Genomics leadership team is here all week and we’d be happy to connect and compare notes.

#jpm2026 #Genomics

VP of Client Service | Leading Enterprise AI Partnerships | Team Builder | Author of Mastering AI Sales | MBA, MSc.

JPM was an outstanding experience. The energy, quality of conversations, and level of innovation throughout the week were exceptional.

We were delighted to host a Genomics reception, where we shared how Mystra, our AI enabled platform, enables teams to apply human genetics more effectively to R&D decision-making. The depth of engagement reinforced just how central genetics has become to smarter target selection and clinical decisions.

A few key takeaways stood out for me…

1. Platforms must change decisions
AI creates value only when it changes decisions e.g. which targets advance, which programs stop earlier, and which patients enter trials. The strongest platforms enable fewer, higher-confidence bets.

2. Data advantage ≠ more data
The ultimate advantage is signal, not scale. Rare disease cohorts, longitudinal datasets, and multi-omics data with clinical context enable better questions to be asked and reduce false confidence.

3. Causal genetics is becoming foundational
Human genetics is increasingly being used to improve probability of success, de-risk programs earlier, enable patient stratification, and support smarter trial design.

The next phase of R&D won’t be defined by who moves fastest, but by who makes the best decisions earliest, using well-curated data, causal evidence, and AI together.

#JPM26 #Genetics #TargetValidation #PatientStratification #DrugDevelopment

I'll be heading to JPM next week. If you’ll be there too, drop me a message, it’d be great to connect in person.

🎉 We're starting the year in San Francisco! Our team will be arriving later this week for the J.P. Morgan Healthcare Conference.

We are looking forward to a busy few days connecting with colleagues from the Department for Business and Trade, and senior leaders across pharma and biotech.

From Saturday, January 10th, our CEO and Co-Founder, Professor Sir Peter Donnelly, President David Thornton, VP of Client Service David Walker, and Director of Communications Zuzanna Grzeskiewicz will be on the ground in San Francisco, ready to connect.

If you're going to be in San Francisco next week and would like to meet with our team, click here: https://lnkd.in/eT9qFMyy

See you soon! 🚀 

#JPM2026 #JPMWeek #techbio #genomics #JPM #pharma #biotech #healthcare #SanFran

Great to see the Genomics team out in force at #FOG2026 
If you’re at FOG, make sure you stop by by Booth #77 to say hello and check out the Mystra D&D Quest, a fun, hands-on way to experience how we support drug target discovery and development through human genetics and multi-omics.   Plus Dirk Paul, Head of Development, talking about: “The Genome and Beyond: Advancing Drug Discovery and Development” Today 12:00–12:30 | Multi-Omics Stage
Have a great show, team 👋
#DrugDiscovery #MultiOmics #Genomics #DrugDevelopment #FOG2026 #FrontLineGenomics

Day 1 at #FOG2026 is here 🚀 

You can find us at Booth #77 - come say hello to the team and try our iconic Mystra D&D Quest 🧙 - an interactive challenge that gives you a hands-on experience with our drug target discovery and development platform! 

🎤 Today | 12:00 - 12:30 | Multi-Omics stage
Join Dirk Paul, Head of Development, for "The Genome and Beyond: Advancing Drug Discovery and Development"
What to expect:
💡 Insights into Genomics' genotype-phenotype platform & analytical pipelines
🧬  A deep dive into how multi-omics integration drives target identification & data-driven patient stratification
🌍  Real-world case case studies showcasing risk prediction and pharmacomimetic approaches in action

See you on the floor 👋 

#drugdiscovery #MultiOmics #Genomics #DrugDevelopment Front Line Genomics

Capgemini

Leading the Global Life Sciences Technical Operations Practice for the Capgemini Group, driving process and digital solutions for Pharmaceutical and Medical Device clients in Supply Chain, Manufacturing, Quality, Technical Transfer, and related functionalities. Focused on strategy and offerings, alliances, marketing and thought leadership and expertise development in support of client excellence.

Vice President, Global Life Sciences Technical Operations

Chamber Music Pittsburgh

Chamber Music Pittsburgh (CMP) presents world class chamber music ensembles and soloists, promising emerging artists and innovative programs. In addition, CMP fosters an appreciation for chamber music in the Pittsburgh community by offering educational programs and experiences. Brian served as a member of the board of directors for CMP.

Board Member

Tata Consultancy Services

Built and led a robust, diverse Life Sciences Technical Operations strategy consulting team. Led support for Pharmaceutical and Medical Device clients in Supply Chain & Manufacturing Operations. Partnered with a wide array of TCS client accounts, functional leaders, delivery providers and Engineering teams to develop and deploy offerings to help clients realize transformational success.

Partner, Life Sciences

Deloitte

Provided consulting services to a variety of Pharmaceutical and Medical Device clients in the areas of Manufacturing, Quality, Launch & Transfer, Operational Excellence and Supply Chain. Led the development and deployment of platform solutions in Technical Transfer and Lean Laboratories. Co-led Deloitte’s Process Intelligence (Lean Six Sigma) practice.

Specialist Leader, Life Sciences Technical Operations

The Capable Process Consulting, LLC

Provided consulting services directly to clients and via sub-contracting with other niche firms. Services include Strategy Formulation, Opportunity Selection, Dashboard Development, Lean Six Sigma and Quality by Design Education and Coaching, cGMP Auditing, Product and Process Risk Assessment, Change Management Facilitation and FDA 483 Response Assistance. Sub-contract partners included Lachman Consultants.

Managing Partner

Viatris

Designed, built, and led the Mylan (now, Viatris) Global Operational Excellence program, delivering a range of sustained benefits in the areas of Right First Time (RFT), production cycle times, support processes in the HR and IT areas, and improved key product yields and OEE levels. Developed and delivered a range of technical learning elements, provided support to product development, scale up and technical problem solving and served key roles in various FDA 483 response and warning letter activities. Recruited, trained, and coached a diverse, global process improvement team.

Vice President, Global Operational Excellence

Merck

Provided direct support to company-wide projects and built and led a diverse global project support and training team for Merck’s Lean transformation. Spearheaded development of an innovative approach to combine Operational Excellence methods with robust Change Management to help address transformation and non-technical area improvements.

Senior Director, Operational Excellence

Wonderful Pistachios & Almonds

Established a Lean transformation program, focusing on procurement, processing, packaging, Quality, and related functional areas. Built a process improvement team and a portfolio of work to help realize recurring savings in cost of goods sold and utilities, substantial cycle time reductions for product launches and the smooth and effective launch of new production lines and brown field built facilities.

Director, Process Engineering

GE Appliances, a Haier company

Led a core group of Scientists and an extended network of Global Program Managers executing new product development and cost reduction projects across GE sites in the Americas, Europe, India and China. Key leadership role in 2 business mergers. Delivered cost structure efficiencies and helped enable division-wide annual cost reductions with zero new product launch misses.

Director, Engineering

Several high impact roles of increasing responsibility:   Black Belt in Manufacturing/Cost Reduction, Master Black Belt Trainer, Business Improvement provider to HR and Legal teams, Global Engineering Manager for Outsourced services, Engineering Manager for product design team.

Manager, Manufacturing Engineering

US Navy

Developed and executed short- and long- range schedules for surface ships, salvage operations and strategic missile placement within the U.S. Navy’s Atlantic Fleet, including deployed operations in the Atlantic, Mediterranean, and Middle East Operating areas. Designed and implemented a range of programs to improve operational efficiency and fleet morale.

Global Scheduling Leader

Serving line officer aboard the USS Theodore Roosevelt (CVN-71). Led a division of 80 skilled mechanics and technicians with responsibility for a variety of mechanical systems. Supervised start up, operation, shut down and maintenance of nuclear power plants and associated systems. Supervised navigation of the aircraft carrier at sea.

Nuclear Engineer and Machinery Division Manager

Brian is an executive and consulting leader in the Life Sciences industry. He has three decades of operations transformation, management consulting and leadership experience. He has developed and led global Lean and Digital programs, consistently recruiting and developing a diverse array of talent and has led global business integrations, executed a range of process and product programs and directly supervised operations of technical processes.
Brian’s experience extends to government, public and private sectors and to the Pharmaceutical, Medical Device, Energy, Consumer Products, and Food Processing industries. He is a Certified Master Black Belt, Change Management Expert, Lean Expert, GE trained executive, Veteran US Naval officer and certified Nuclear Engineer.

Brian Eden

2025 was a landmark year for biopharma innovation. Despite a dynamic regulatory environment, 55 new drugs and biologics were approved—bringing hope and better outcomes to millions of patients worldwide.

Some highlights:

✅ Datroway (#AstraZeneca / #DaiichiSankyo): A next-generation therapy for breast and lung cancer, offering new hope for patients with advanced disease.
✅ Brinsupri (#Insmed): The first treatment for bronchiectasis that targets the root cause, helping patients breathe easier and live fuller lives.
✅ Journavx (#Vertex): A non-opioid pain therapy, giving patients safer options for managing chronic pain without the risks of addiction.
✅ Myqorzo (#Ipsen), Exdensur (#NovoNordisk), Rhapsido (#Pfizer), Imaavy (#Regeneron), and Penmenvy (#Merck): Each addressing critical unmet needs across rare diseases, oncology, and immunology.

Read a 2025 summary here: https://lnkd.in/eXpybKwx

These breakthroughs remind me why we do what we do: to improve lives. At Capgemini, we’re proud to partner with innovators to accelerate scale-up, launch, and production—ensuring continuity of supply so patients receive these life-changing therapies without delay.

Here’s to another year of collaboration, innovation, and impact!! 🌍💡

#innovationinhealthcare #biopharma #druglaunches #patientfirst #CapgeminiLifeSciences #DigitalHealth #AIinLifeSciences #2026Outlook #PharmaCommunity #HealthTech

VP Global Life Sciences @ Capgemini | Process Improvement Expert | Veteran, U.S. Navy

taplio

The Battle

David Walker

Brian Eden

Followers

Posts

Engagements

Likes

Performance ScoreDavid Walker's LinkedIn Performance

Performance ScoreBrian Eden's LinkedIn Performance

Ready to grow your LinkedIn presence?

taplio

The Battle

David Walker

Brian Eden

Followers

Posts

Engagements

Likes

Performance Score.css-goub6s{font-size:var(--chakra-fontSizes-md);font-weight:500;color:var(--chakra-colors-gray-600);display:block;margin-top:var(--chakra-space-1);}David Walker's LinkedIn Performance

Performance ScoreBrian Eden's LinkedIn Performance

Ready to grow your LinkedIn presence?

Performance ScoreDavid Walker's LinkedIn Performance